GLP-1 Medications: A Plain-English Overview

What a GLP-1 receptor agonist is

Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases when you eat. It's one of several "incretin" hormones, and it does a few things at once: it prompts the pancreas to release insulin when blood sugar is elevated, dampens the release of glucagon (a hormone that pushes blood sugar up), slows how quickly the stomach empties, and signals to areas of the brain involved in appetite and fullness.

Natural GLP-1 breaks down within minutes. A GLP-1 receptor agonist is a manufactured molecule shaped to bind the same receptor and produce a similar signal, but engineered to last far longer — long enough to be dosed once a day or once a week.

Two details matter. The insulin effect is glucose-dependent, which is part of why the class carries a lower intrinsic risk of hypoglycemia than insulin itself, though that risk rises in combination with insulin or sulfonylureas. And the appetite and stomach-emptying effects aren't a side channel — they're part of the same hormonal signal, which is why one mechanism underpins both the diabetes and the weight-management indications.

The classes that get grouped together

In everyday use, "GLP-1" is a loose label covering several related but genuinely distinct groups of medications. Telling them apart matters, because each carries its own approvals, warnings, and body of evidence.

• GLP-1 receptor agonists. The original group, acting on the GLP-1 receptor alone. Molecules here include exenatide, liraglutide, dulaglutide, and semaglutide. They differ from one another in dosing frequency, route of administration, and which indications each has been approved for.
• Dual GIP/GLP-1 receptor agonists. A single molecule engineered to act on the receptor for glucose-dependent insulinotropic polypeptide (GIP) — a second incretin hormone — as well as the GLP-1 receptor. Tirzepatide is the molecule in this group with U.S. approvals. Press coverage routinely calls it "a GLP-1," which is imprecise: it's a related but separate class with its own label.
• Peptide versus small-molecule. Most medications in this category are peptides, which is largely why they're injected. A separate line of development uses small non-peptide molecules intended to activate the same receptor in tablet form; those remain investigational in the U.S. (see below).

Worth distinguishing from all of the above: DPP-4 inhibitors, an older oral class that slows the breakdown of the GLP-1 your own body makes rather than mimicking it. They act on the same hormonal pathway, which is why they're sometimes confused with receptor agonists, but they are a different class with a different clinical profile and different labelling.

What they're approved to treat

In the United States, approvals are granted product by product and indication by indication, not to a class as a whole. Two products in the same class can carry different approved uses, age ranges, and warnings. Broadly, medications in this class have been approved for:

"Approved" is always a question of which product, which dose, which indication — never of the class as a whole.

• Type 2 diabetes — improving blood sugar control in adults, alongside diet and exercise. This was the original indication.
• Chronic weight management — for adults meeting specific body-mass-index criteria, typically a BMI at or above 30, or at or above 27 with a weight-related health condition, again alongside diet and activity.
• Cardiovascular risk reduction — several products carry indications for reducing major cardiovascular events in defined populations, based on dedicated outcome trials.
• Other condition-specific approvals exist for particular products, in areas such as chronic kidney disease in type 2 diabetes and obstructive sleep apnea in adults with obesity.

Type 1 diabetes is not an approved indication. Prescribing outside an approved indication — "off-label" use — is legal and common in U.S. medicine, but it matters practically, because insurers often draw coverage lines exactly where the label does. That's the subject of a separate guide.

How the approvals accumulated

The category didn't arrive fully formed. It was built up in increments over roughly two decades, and the sequence explains much about how these medications are prescribed and covered today. Using molecule names rather than brand names, the broad arc in the U.S. looks like this:

• 2005 — the first GLP-1 receptor agonist was approved for type 2 diabetes (exenatide, a twice-daily injection). Blood sugar control was the entire purpose; effects on body weight were an observation, not an indication.
• 2010 onward — longer-acting versions were approved for type 2 diabetes (liraglutide, then dulaglutide and others), moving dosing from twice daily toward once daily and then once weekly.
• 2014 — the first chronic weight management indication. Liraglutide was approved at a higher dose for adults meeting specific BMI criteria. Note the structure, because it recurs: the same molecule, a higher dose, a separate application, a separate label, a separate brand.
• 2017 and 2019 — semaglutide was approved for type 2 diabetes as a weekly injection, and then in a daily oral tablet — the first oral formulation in the class.
• 2021 — semaglutide for chronic weight management at a higher dose, again as its own product and indication.
• 2022 and 2023 — the first dual GIP/GLP-1 receptor agonist, tirzepatide, was approved for type 2 diabetes and subsequently for chronic weight management.
• Cardiovascular, kidney, and sleep-apnea indications followed for particular products, each granted on the strength of its own dedicated outcome trial rather than extended automatically across the class.

Two consequences are worth holding onto. First, "approved" is always a question of which product, which dose, which indication — never of the class as a whole. Second, the diabetes indications came first and are the longest-established with insurers, which is the origin of most coverage disputes over weight-management prescriptions.

How they're taken

Most are given as a subcutaneous injection — into the fat just under the skin of the abdomen, thigh, or upper arm — from a pre-filled pen with a short, fine needle, self-administered at home either once daily or once weekly.

An oral tablet formulation also exists. Because the active molecule is a peptide, absorption from the gut is inefficient and highly sensitive to conditions in the stomach, so oral versions carry strict instructions: once daily on an empty stomach, with no more than a sip of water, and a waiting period before eating or taking other oral medications.

Nearly all products in this class start low and step up over weeks — a process called titration. It exists mainly to let gastrointestinal effects settle, not because the starting dose is the therapeutic one.

Side effects, in categories

Profiles differ between products, and only the specific label and your prescriber can tell you what applies to you. These categories recur across the class.

• Gastrointestinal effects are the most commonly reported: nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, reduced appetite. They cluster around dose increases and often ease with time — hence the deliberately slow titration.
• Injection-site reactions — redness, itching, a small lump — are usually mild and local.
• Low blood sugar is uncommon with these medications alone, but becomes a real consideration alongside insulin or sulfonylureas, sometimes requiring those doses to be adjusted.
• Less common but serious concerns in class labelling include pancreatitis, gallbladder disease, kidney problems from dehydration after prolonged vomiting or diarrhea, serious allergic reactions, and changes in diabetic retinopathy. Products in this class also carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and are contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Procedural and pregnancy considerations — because these medications slow stomach emptying, anesthesia teams have issued guidance on fasting and aspiration risk before sedation, so surgical and dental teams should be told. They are generally not used during pregnancy.

What the approval process looks like

Before a medication in this class reaches a U.S. pharmacy it moves through a defined sequence: laboratory and animal studies, an Investigational New Drug application to the FDA, then human testing in phases — small Phase 1 studies of safety and dosing, Phase 2 studies seeking a dose that works, and larger Phase 3 trials against placebo or an existing treatment.

The sponsor then submits a marketing application with the full dataset. FDA reviewers assess it, sometimes with an independent advisory committee, and either approve it with specific labelling — indication, dosing, contraindications, warnings — or decline. Scrutiny continues afterwards through required post-marketing studies and adverse-event reporting, which is how labels change years after launch. Each new indication generally needs its own application and its own trials.

What's in development — and not approved

This is an active research area, so you'll encounter names in the press that you cannot get by prescription. Two come up most often:

• Retatrutide — an investigational molecule designed to act at three receptors at once: GIP, GLP-1, and glucagon. Phase 2 findings have been published in the peer-reviewed literature (Jastreboff AM et al., The New England Journal of Medicine, 2023), and a phase 3 programme has been running since.
• Orforglipron — an investigational once-daily oral small-molecule GLP-1 receptor agonist. Because it isn't a peptide, it is not expected to carry the strict food-and-water instructions that oral peptide formulations require. Phase 2 findings have likewise been published (Wharton S et al., The New England Journal of Medicine, 2023), with phase 3 trials following.

We name these because you'll see them referenced, and because the published phase 2 reports are public documents you can read yourself. We're deliberately not summarising their results: phase 2 findings in selected populations are a poor guide to what a final label will say, and quoting figures out of that context is how expectations get set badly.

Why this class has drawn so much clinical attention

Part of the answer is that it turned out to do more than one thing. A medication developed for blood sugar control also influenced appetite, body weight, and — in dedicated outcome trials — endpoints that cardiologists and nephrologists care about. That breadth pulled several specialties into the same literature.

The other part is the evidence base. Large randomized cardiovascular outcome trials became a regulatory expectation for diabetes drugs after 2008, so this class has been studied in tens of thousands of participants with pre-registered endpoints and independent event adjudication. Readers who want the primary sources rather than the coverage might start here.

We cite these because they're named, peer-reviewed, and publicly retrievable — not to suggest what any of them means for you. Trial populations are selected, results are averages, and none of it substitutes for a clinician who knows your history. If you're heading into that conversation, our list of questions to ask is a reasonable place to start.